On May 9, 2025 Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, reported financial results and business highlights for the fiscal quarter ended March 31, 2025 (Press release, Boundless Bio, MAY 9, 2025, View Source [SID1234652819]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers," said Zachary Hornby, President and CEO of Boundless Bio. "We look forward to providing a clinical data update on our BBI-355 program later this year. Additionally, we expect to nominate a development candidate for our novel Kinesin program by mid-year, with plans to submit an IND in the first half of 2026."
Research and Development Highlights and Upcoming Milestones
BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers
•
Enrollment is ongoing in the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept safety and antitumor activity data are expected in the second half of 2025.
Novel Kinesin program targeting ecDNA segregation and inheritance
•
Boundless expects to nominate a development candidate for its preclinical program targeting a previously undrugged kinesin by mid-2025, with an investigational new drug (IND) submission planned for the first half of 2026.
Recent Data Presentations
•
Preclinical data from studies conducted with Boundless’s ribonucleotide reductase (RNR) inhibitor, BBI-825, were presented in an oral session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting. These data suggest that the combination of BBI-825 with mutant-specific, pan, and multi-RAS targeting inhibitors delayed or prevented acquired resistance in colorectal cancer preclinical models. Boundless continues to preclinically evaluate BBI-825 in various treatment settings.
First Quarter 2025 Financial Results
•
Cash Position: Cash, cash equivalents, and short-term investments totaled $138.3 million as of March 31, 2025.
•
Research and Development (R&D) Expenses: R&D expenses were $12.1 million for the first quarter of 2025, compared to $13.1 million for the same period in 2024.
•
General and Administrative (G&A) Expenses: G&A expenses were $5.2 million for the first quarter of 2025, compared to $3.8 million for the same period in 2024.
•
Net Loss: Net loss totaled $15.8 million for the first quarter of 2025, compared to $15.4 for the same period in 2024.